实用医学杂志 ›› 2020, Vol. 36 ›› Issue (20): 2830-2833.doi: 10.3969/j.issn.1006⁃5725.2020.20.017

• 药物与临床 • 上一篇    下一篇

卡瑞利珠单抗联合化疗对老年非小细胞肺癌患者血清细胞角蛋白19片段抗原21⁃1、基质金属蛋白酶9 表达及肿瘤生长转移的影响

吴克林1 吴天英1 许海2   

  1. 1 荆州市第一人民医院老年医学科(湖北荆州434007);2 湖北中医药大学黄家湖医院妇科(武汉430070)
  • 出版日期:2020-10-20 发布日期:2020-10-25
  • 基金资助:
    中国博士后科学基金(编号:2013M542498);湖北省自然科学基金(编号:2018CFC808)

The effect of camrelizumab monoclonal antibody combined with chemotherapy on serum CY211,MMP⁃9 expressions and tumor growth and metastasis in elderly patients with non⁃small cell lung cancer

WU Kelin*,WU Tianying,XU Hai   

  1. *Department of Geriatrics,the First People′s Hospital of Jingzhou,Jingzhou 434007,China
  • Online:2020-10-20 Published:2020-10-25

摘要:

目的 观察卡瑞利珠单抗联合化疗对老年非小细胞肺癌(NSCLC)患者血清细胞角蛋白19片段抗原21⁃1(CY211)、基质金属蛋白酶9(MMP⁃9)表达及肿瘤生长转移的影响。方法 选取2017年1月至2019年10月在本院就诊的老年NSCLC患者120例,随机分为观察组和对照组各60例,对照组给予化疗方案治疗,观察组给予卡瑞利珠单抗联合化疗方案治疗,3个周期后进行疗效评价,并比较两组患者治疗前后血清CY211、MMP⁃9表达及肿瘤生长转移的变化情况。结果 治疗后,观察组总有效率显著高于对照组(P < 0.05);两组患者血清CY211、MMP⁃9、血管内皮生长因子(VEGF)表达水平均较治疗前降低,观察组低于对照组(P < 0.05);两组卡氏生存质量(KPS)评分均较治疗前提高,观察组高于对照组(P < 0.05)。结论 卡瑞利珠单抗联合化疗对老年NSCLC 患者疗效显著,可显著降低患者血清CY211、MMP⁃9、VEGF水平,减少新生血管生成及抑制肿瘤生长转移,提高患者生存质量。

关键词: 卡瑞利珠单抗, 化疗, 非小细胞肺癌, 细胞角蛋白19片段抗原21?1, 基质金属蛋白酶9, 生长转移

Abstract:

Objective  To observe the effects of camrelizumab monoclonal antibody combined with chemo⁃therapy on the expressions of cytokeratin 19 fragment antigen 21⁃1(CY211),matrix metalloproteinase⁃9(MMP⁃9)and tumor growth and metastasis in elderly patients with non⁃small cell lung cancer(NSCLC). Methods  FromJanuary 2017 to October 2019,120 elderly NSCLC patients were randomly divided into observation group andcontrol group,with 60 cases in each group. The control group was treated with chemotherapy,while the observationgroup was treated with camrelizumab monoclonal antibody combined with chemotherapy. The therapeutic effect wasevaluated after 3 cycles,and the changes of serum CY211,MMP⁃9 expressions and tumor growth and metastasiswere compared before and after treatment. Results  After treatment,the total effective rate of the observationgroup was significantly higher than that of the control group(P < 0.05). The levels of serum CY211,MMP⁃9 andvascular endothelial growth factor(VEGF)in the two groups were lower than those before treatment,and the obser⁃vation group was lower than the control group(P < 0.05). The Karnofsky Performance Scale(KPS)score of bothgroups was higher than that before treatment,and the observation group was higher than the control group(P <0.05). Conclusions Camrelizumab monoclonal antibody combined with chemotherapy has a significant effect onelderly NSCLC patients,which can significantly reduce the levels of serum CY211,MMP⁃9 and VEGF,reduceneovascularization,inhibit tumor growth and metastasis,and improve the quality of life of the patients.

Key words: camrelizumab monoclonal antibody, chemotherapy, non?small cell lung cancer, cyto?keratin 19 fragment antigen 21?1, matrix metalloproteinase?9, growth and metastasis